Apoliktos is a preinception-stage biotech in immuno-oncology with an international team of experts and founders aiming to develop personalized therapeutics against multiple myeloma.
Apoliktos is establishing a platform, which uses a modular library of neoantigen binders and antibody backbones connected at the patient’s bedside for targeted personalized therapeutic antibodies.